Form 8-K · Current Report · Filed 2024-07-23
Moderna Announces Board Changes with Appointment of David Rubenstein and Departures of Robert Langer and Stephen Berenson
On July 19, 2024, Moderna, Inc. announced via an 8-K filing that Robert Langer and Stephen Berenson will resign from the Board of Directors, effective August 5, 2024. Simultaneously, the Board appointed David M. Rubenstein, Co-Founder and Co-Chairman of The Carlyle Group, to the Board, effective the same date. Rubenstein will also serve on the Audit Committee. Both departing directors will provide consulting services to Moderna. The information was also disclosed in a press release dated July 23, 2024, furnished as Exhibit 99.1.
- Filer
- Moderna Inc. MRNA · NASDAQ
- Filed
- Accession
- 0001682852-24-000035
- CIK
- 0001682852
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Regulation FD Disclosure
Financial Statements and Exhibits
Market reaction
Close before filing
$122.50
Next session
-3.5%
Since filing
-55.2%
Latest close
$54.82
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from MRNA reporting the same item, with the next session's move:
Exhibits (1)
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Never miss another MRNA filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.